Medarex, Inc. has announced the filing of an Investigational New Drug (IND) application in the Netherlands by its licensing partner, NovImmune SA, for NI- 0401, a fully human antibody that targets the CD3 antigen, for the treatment of autoimmune disease.
The antibody product was developed using Medarex's UltiMAb® technology.
Medarex expects to receive an undisclosed milestone payment and may receive future milestone payments and royalties should this product candidate progress through clinical development.
"We are pleased with the progress that our partner, NovImmune, has achieved in filing an IND," said Donald L. Drakeman, President and CEO of Medarex, Inc.
"With the advancement of the NovImmune antibody into clinical trials, there are now twenty-nine fully human antibodies generated from Medarex's technology that are in clinical development by Medarex and its partners."